Associations

Life Member: NY State Medical Society

Web Strategy Committee for American Society of Lasers in Medicine & Surgery 2017

Scientific Advisory Board – American Council Science & Health 2016

Founding Member, 2015 International Dermal Ultrasound Society

Member, Greater NY Dermatology Society 2015

Founding Member, 2014 American Cutaneous Cancer Society

American Society Lasers in Medicine & Surgery 2014-present

European Society of Radiology 2014

Member, Mt Sinai Melanoma Group 2013

Click HERE for complete list of Associations

Communication Representative, American Institute of Ultrasound in Medicine 2012

Visiting Professor Service d’Oncologie, Hopital Pitie-Salpetriere Paris, 2008

Visiting Professor Dept. of Dermatology, Mount Sinai Medical School 2007

International HIFU Society 2006

Societe d’Imagerie Ultrasonore 2005

Prostate Cancer Focused Ultrasound Certification 2005, US HIFU Prostate Institute

Visiting Professor Dept of Urology 2004, Maimonides Hospital of Mt Sinai Med School

Founder, Biofoundation for Angiogenesis Research 2001

Societe Francaise de Radiologie 2001

Key Speaker Foot and Ankle Ultrasound Colorado Podiatric Medical Association Steamboat Springs 2000

President, Tendon Ultrasound Section, 5th International Congress of Musculoskeletal
Sonography Prague 2000

NY Metropolitan Breast Cancer Group 1999

International Cancer Imaging Society 1998

Director, Robert Bard MD PC 1994-present

2017 DEMUS GROUP teaching presentation on skin cancer imaging at the world conference Americal Institute of Ultrasound Medicine- Orlando, Fla. March, 2017

Did You Know…

Dr. Bard is the only American member of the International Dermal Ultrasound Group with physicians selected from 12 participating nations worldwide. (Visit our expanded NEWS section)

NON-INVASIVE PROSTATE CANCER DIAGNOSIS

Until recently, standard prostate cancer screening consisted of a PSA blood test (Prostate Specific Antigen) and DRE (Digital Rectal Exam). In 2017 a U.S. Government Panel released a statement suggesting such screening had a high cost with doubtful survival advantage. In other words, too many men whose screening revealed a suspiciously high PSA or abnormal DRE were rushed into multi-needle biopsies that entailed risks of false negatives, infection, and sexual side effects. (MORE)

The Bard Cancer Center is founded on the commitment to explore and implement the latest diagnostic technologies as a means of building the proper treatment strategy of many types of cancers. We also specialize in the PREVENTION solutions for our patients who strive to maintain a health-conscious lifestyle as well as those who are at increased risk of certain diseases by confirming that their efforts to prevent disease are working.

BARD CANCER CENTER

121 E. 60th St. Suite #6A New York, NY 10022
212.355.7017
Info@bardcancercenter.com